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Oesophageal carcinoma is a common cancer in China and Taiwan
(Wu et al, 1980; Wang et al, 1992). Its annual incidence rate varies
from 3/105 to 25/105, depending upon genetic vulnerability, diet
and environmental factors. Surgery is a curative treatment for the
early stage oesophageal squamous cell carcinoma (ESCC) (Katlic
et al, 1990; Wang et al, 1996), however, most patients present with
advanced disease. Furthermore, poor prognosis is compounded
with the rapid growth and spread of cancer cells as well as
dysphagia-associated malnutrition and cachexia (Katlic et al,
1990; Strassmann and Jacob et al, 1992). The effort of multiple
therapeutic modalities was not beneficial for patients at late stage.
Therefore, a method for identifying the disease progression of
ESCC and the potential of cancer cell spreading is important to
commence the early treatment and to improve survival.
Interleukin-6 (IL-6), besides being a multi-functional cytokine
with a wide spectrum of immunological activities (Kishimoto,
1990), is a potent endogenous pyrogen (Gauldie et al, 1987;
Castell et al, 1990) and a potential mediator in the development of
cancer cachexia (Strassmann and Fong et al, 1992). It has been
detected in primary squamous cell carcinomas, adenocarcinomas
and sarcomas (Tabibzadeh et al, 1989), as well as tumour cell lines
derived from melanoma (Lee et al, 1992), glioblastoma (VanMeir
et al, 1990; Stephanou et al, 1992), lung cancer (Takizawa et al,
1993; Takeuchi et al, 1996; Inoue et al, 1997), ovarian cancer
(Watson et al, 1990) and cervical cancer (Eustace et al, 1993).
Clinically, serum levels of IL-6 were also demonstrated to corre-
late with adverse prognosis in patients with metastatic renal cell
carcinoma (Blay et al, 1992), ovarian cancer (Scambia et al, 1995),
gastric cancer (Kabir and Daar, 1995; Wu et al, 1996), lung cancer
(Yanagawa et al, 1995; Wojciechowska-Lacka et al, 1996) and
Hodgkin’s lymphoma (Seymour et al, 1997).
In vitro, IL-6 was further shown to act as an autocrine growth
factor in stimulating the proliferation of multiple myeloma
(Kawano et al, 1988), renal cell carcinoma (Mini et al, 1989) and
non-Hodgkin’s lymphoma cells (Ni and O’Neill, 1992). Recently,
Oka et al (1996) showed that ESCC could also express both IL-6
and its receptor (IL-6R). It is conceivable that IL-6 could have
pathogenetic significance in disease progression of this malig-
nancy. Nonetheless, the induction effect of IL-6 on tumour cell
growth might not be invariably obtained (Yanagawa et al, 1995).
The difference could be in part due to the marked heterogeneity of
gene expression in a tumour cell population. In part, IL-6 gene
may not be expressed constitutively. It might be subjected to a
pathophysiological regulation in cancer cells. A recent study has
indicated that both urinary butyrate concentration and IL-6 level
were increased in AIDS patients with significant weight loss
(Stein et al, 1997), a condition that is similar to what a cancer
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Taipei 11217, Taiwan, ROCpatient could develop during cachexia (Strassmann et al, 1992).
Butyrate is a short-chain fatty acid produced by intestinal bacteria
that could escape from the host immunosurveillance in intestine
during disease progression. Serum butyrate concentration could
therefore reflect the intestinal situation, and it is reasonable to ask
whether butyrate could have any effect on IL-6 expression at the
advanced stage of ESCC.
In this study, we examined serum levels of IL-6 in 80 ESCC
patients and relationships among serum IL-6 level, clinicopatho-
logical factors and survival following surgery. Furthermore, we
indentified the source of serum IL-6 by examinations of IL-6, IL-6
mRNA and IL-6 receptors in tumour specimens and the ESCC cell
lines, and characterized the physiological regulation of IL-6
expression by n-BT. The role of IL-6 in autocrine growth regula-
tion for ESCC would then be discussed.
METHODS
Human sera, tissue specimens and tumour cell lines
From February 1993 to November 1997, sera and tissue specimens
from 80 consecutive patients with newly diagnosed oesophageal
cancer were collected. All patients had pathologically confirmed
oesophageal squamous cell carcinoma (ESCC). The preoperative
work-up consisted of oesophagoscopy with biopsy, oesophago-
gram, chest radiography, sonogram of the abdomen, computerized
tomography (CT) scan of the chest and radionuclide scanning of
whole body bone. All patients underwent en bloc oesophagectomy
with locoregional lymphadenectomy through a right thoracotomy
and laparotomy with reconstruction using the stomach through a
retrosternal route, and cervical oesophagogastrostomy (Liu et al,
1998; Wang et al, 1998). Concurrent chemoradiotherapy would be
administered after surgery for patients with stages beyond IIb
(Wang et al, 1996, 1998). However, none received neoadjuvant
therapy in the present series. After treatment, all patients were
followed as routine. Stage of disease progression was classified
according to the Union International Centre Cancer system. All
stage IV patients were due to distant lymph node metastasis
(cervical, coeliac, or para-aortic regions, etc.). Sera and peripheral
blood cells were collected from patients at the time of diagnosis,
four times at 3-month intervals, and then 6-month intervals
following treatment. Sera from 103 healthy donors with an
equivalent distribution of age and sex were collected as normal
control. The Medical Ethical Committee approved the protocol,
and the study was strictly following their guidelines. Written
informed consent was obtained from every patient. A single-blind
procedure was followed to carry out enzyme-linked immunosor-
bent assay (ELISA), immunostaining (IMS) and in situ hybridiza-
tion (ISH) protocols. Three ESCC cell lines (48T, 81T and 146T,
obtained from Dr CP Hu, Department of Medical Research,
Veterans General Hospital–Taipei) were used for in vitro study.
Up-regulation of IL-6 by n-BT was studied in ESCC cell lines.
The expression of IL-6 mRNA in the cancer cell lines was
confirmed in ESCC cells with ISH and reverse transcription poly-
merase chain reaction (RT-PCR) method. Cells were grown at
37°C in a monolayer in RPMI-1640 supplemented with 10% fetal
calf serum, 100 IU ml–1 penicillin and 100 mg ml–1 streptomycin.
ELISA
The concentration of serum IL-6 was determined by ELISA with
Quantikine HS human IL-6 (R & D Systems Inc., Minneapolis,
MN, USA). Briefly, 50 ml of assay diluent were added to a well
that was pre-coated with monoclonal antibody specific to IL-6,
before addition of 200-ml sample. The reaction was incubated at
room temperature for 16 h. The microtitre plate was washed with
wash buffer four times, and 200 ml of alkaline phosphatase-conju-
gated polyclonal antibody specific to IL-6 was then added. The
reaction was further incubated at room temperature for 6 h. After
washing four times with wash buffer, 50 ml of NADPH was added,
and reaction was incubated at room temperature for 60 min. A
positive reaction was identified by developing with amplifier solu-
tion containing diaphorase and INT-violet at room temperature for
30 min, and by reading at A490 nm (MRX, Dynatech Laboratories
Inc., Chantilly, VA, USA). Each individual sample was analysed in
duplicate. Samples with overscaled values were diluted before
further determination. Additionally, levels of sCD8 was also
measured by ELISA with CD8 test kit (T cell Diagnostics,
Cambridge, MA, USA).
Immunological staining
Immunological staining was used to detect the expressions of IL-6
and its receptors, IL-6Ra and gp 130 (IL-6 signal transducer), in
the cancer cell lines and pathological sections. Antibodies used for
immunological staining were specific to IL-6, IL-6Ra (R&D
Systems Inc., Minneapolis, MN, USA) and gp130 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) respectively.
Immunological staining was performed by an immunoperoxidase
method as previously described (Chiu et al, 1997).
ISH
A non-isotopic method, using a mixture of fluorescein isothio-
cyanate (FITC)-labelled IL-6 antisense oligonucleotides, was used
to determine the expression of IL-6 mRNA in cell lines and
pathological sections (Chow et al, 1992). The probe sequences
were (Wang et al, 1988): 5¢-GGACAGGTTTCTGACCAGA-
AGAA GGAATGCCC-3¢ (IL-6 mRNA, 750–719) 5¢-ACT-
GCAGGAACTCCTTAAAGCTGCGCAGAA-3¢ (IL-6 mRNA,
660–631) 5¢-TCACCAGGCAAGTCTCCTCATTGAATCCAG-3¢
(IL-6 mRNA, 390–361). Hybridization products were visualized
by using alkaline phosphatase-conjugated polyclonal antibodies to
FITC (Amersham International, Buckinghamshire, UK) and chro-
mogen NBT/BCIP (Sigma, St Louis, MO, USA). Positive staining
was identified microscopically as brownish blue granules at the
site of hybridization.
RNA extraction and signal amplification (RT-PCR)
Total RNA was extracted from 1 ´ 107 ESCC cells using SNAP
RNA column (Invitrogen Corporation, San Diego, CA, USA).
Following spectrophotometric determination of total RNA yield,
cDNA was synthesized by oligo dT primer and AMV reverse tran-
scriptase. An aliquot of cDNA was then subjected to 35 cycles of
PCR using standard procedure denaturing at 94°C for 1 min,
hybridizing at 52°C for 30 s, and elongating at 72°C for 1.2 min.
The primers were 5¢-CTGGATTCAATGAGGAGACTTGC-3¢
(IL-6 mRNA, 361–383, sense primer) and 5¢-GGACAGGTTTCT-
GACCAGAAG-3¢ (IL-6 mRNA, 750–730, antisense primer). The
amplified products were resolved in a 2.5% agarose-ethidium
bromide gel. Specificity of the 390 base-pair amplified product
was confirmed by DNA sequencing (ABI Prism, Foster City, CA,
USA).
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The relation between serum level of IL-6 and clinicopathologic
parameters (age, stage, lymph node metastasis, tumour depth) was
analysed by c2 analysis (or Fisher’s exact test when expected
number of any cell was smaller than or equal to five cases).
Survival curves were plotted with the method of Kaplan–Meier
(Kaplan and Meier, 1958). A total of 59 patients entered the
survival curve analysis because of the necessity of an adequate
follow-up period (ù12 months). Statistical differences in survival
between different groups was compared by the log-rank test (Peto
and Pike, 1973). Statistical analysis was performed using SPSS
statistical software (Chicago, IL, USA).
RESULTS
Elevated serum concentrations of IL-6 in patients with
ESCC
The average age of male patients (n = 76) was 63.39 ± 10.9 years
and that of female patients (n = 4) was 62.25 ± 3.86 years.
Preoperative serum IL-6 levels in 93.8% (75/80) of ESCC patients
(12.8  ± 12.1 pg ml–1) were above normal average (2.8 ± 0.9
pg ml–1, n = 103). Among these patients, 61.3% (46/75) were
above 9 pg ml–1. ESCC patients were then divided into two groups
based on the preoperative serum levels of IL-6. In group A
(n = 46), IL-6 levels were ³ 9 pg ml–1, and in group B (n = 34),
IL-6 levels were < 9 pg ml–1. No significant age difference was
found between group A (64.06 ± 10.0 years) and group B (62.35 ±
11.35 years). By c2 analysis, among the TNM categories only
lymph node metastasis (N status) correlated with serum IL-6 level
and that accounted for the overall correlation of the TNM classifi-
cation with serum IL-6 (Table 1). In 15 patients with persistent
high levels of serum IL-6 or a marked increase of serum IL-6 level
within a short interval (0.5–3 months) following oesophagectomy,
all patients developed tumour of recurrence within 12 months after
surgery. On the other hand, most patients with low preoperative
serum levels of IL-6 (n = 21) or those with a decrease of serum
IL-6 level following oesophagectomy (n = 23) could remain
disease-free for 12–23 months (30/44, 68.2%). Relationship
between serum IL-6 level and survival was shown in Figure 1.
The cumulative 2-year survival rate for patients in group A was
26.3% and that in group B was 66.7%. The group B patients had
a superior survival rate compared to the group A patients
(P = 0.0086).
Expression of IL-6 and IL-6Ra in pathological sections
and cancer cell lines
Pathological sections and cultured cells were used for ISH to
determine the expression of IL-6 mRNA. In Figure 2A, the
hybridized products were identified in tumour cells. IL-6 mRNA
was strongly expressed in 37.5% (30/80) of the pathological
sections. IL-6Ra and gp130, however, were detected in 88.7%
(71/80) of pathological sections. In the neighbouring lymphocytes
of the pathological sections, on the other hand, IL-6 mRNA was
only detected in three cases (3.8%). Levels of sCD8 and lympho-
cyte counts in the peripheral blood were not parallel to the change
pattern of IL-6 either (data not shown). All patients with strong
expression of IL-6 (n = 30) in pathological sections had a high
level of serum IL-6 (³ 9 pg ml–1). These data indicate that tumour
cells could be one of the major source of elevated serum IL-6
in patients with ESCC. The striking differences in disease
progression, lymph node involvement and patients’ survival rate
suggested that IL-6 expression may vary among different patients,
although the physiological factors remain to be determined.
Interestingly, there was a substantial increase of IL-6 expression
when ESCC cell lines were treated with n-BT (Figure 2B,C).
This issue was clarified when IL-6 mRNA was examined in
n-BT-treated and control cells by RT-PCR (Figure 3). The differ-
ence was further extrapolated by a serial dilution of cDNA before
PCR. The consequent determination of IL-6 content in the condi-
tioned media of ESCC cell lines supported such observations. A
marked increase of IL-6 in supernatant was detected in 81T cells
(protein from 15.5 pg ml–1 to 244 pg ml–1, 64-fold increase in
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Table 1 Relationship between serum levels of IL-6 and clinicopathological
factors
Groupa
Clinicopathological factors A B c2 P
Lymph node metastasis
Negative 14 21 7.733 0.0056
Positive 32 13
Tumour depth
No invasion to adventitia 11 16 5.004 0.086
Invasion to adventitia 28 13
Invasion to adjacent organ 7 5
Distant metastasis
Negative 33 30 3.312 0.081
Positive 13 4
Stage (TNM)
I 3 10 12.85 0.005
II 9 11
III 15 8
IV 19 5
aGroups were divided by serum levels of IL-6. In group A, IL-6 levels were
³ 9 pg ml–1, and in group B, IL-6 levels were < 9 pg ml–1.
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Figure 1 Comparison of Kaplan–Meier product limit estimates of overall
survival and survival analysis between group A (serum IL-6 levels were
³ 9 pg ml–1) and group B (serum IL-6 levels were <9 pg ml–1). Survival
difference between groups was compared by the log rank test. P = 0.0086cDNA). Smaller changes of IL-6 were observed in 48T (protein
from 6.9 pg ml–1 to 13.4 pg ml–1, fourfold increase in cDNA) and
146T cells (protein from undetectable to 2.6 pg ml–1, 16-fold
increase in cDNA). These results showed that n-BT could play a
role in the upregulation of IL-6 expression in ESCC cells.
DISCUSSION
Coexpression of IL-6 and IL-6 receptor (IL-6R) in cancer cells
has, in recent years, provoked a hypothesis of autocrine growth
factor mechanism (Kawano et al, 1988; Miki et al, 1989; Ni and
O’Neill, 1992). IL-6 mediates its effects through two membrane
proteins, a ligand-binding protein molecule (IL-6R) (Yamasaki
et al, 1988) and a non-ligand-binding signal transducer (gp130)
(Taga et al, 1989). Current evidence suggests that independent of
direct interaction with T lymphocytes and natural killer cells IL-6
could promote tumour cell proliferation in several tumour cell
lines (Kawano et al, 1988; Miki et al, 1989; VanMeir et al, 1990;
Watson et al, 1990; Ni and O’Neill, 1992; Eustace et al, 1993; Oka
et al, 1996; Takeuchi et al, 1996). Murine model as well as a study
of human cervical carcinoma xenograft further support that IL-6
could promote tumour progression (Tamura et al, 1995). Besides
having the ability to impair natural killer functions (Tanner and
Tosato, 1991), IL-6 was shown to be a potent endogenous pyrogen
(Gauldie et al, 1987; Castell et al, 1990) and a potential mediator
in the development of cancer cachexia (Strassmann et al 1992b;
Castell et al, 1990; Strassman et al, 1992a). In spite of these obser-
vations, the mechanism connecting autocrine tumour growth and
development of cancer cachexia remains to be elucidated.
An elegant study by Oka et al (1996) has demonstrated that
oesophageal cancer could express both IL-6 mRNA and IL-6Ra.
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Figure 2 Representative examples of IL-6 expression ESCC cells.
(A) Detection of IL-6 mRNA in ESCC pathological specimen by ISH.
(B) Immunoreactivity of IL-6 was detected in n-BT-treated ESCC
cells. (C) Immunoreactivity of IL-6 was confirmed with ISH in n-BT-treated
ESCC cells (original magnification ´ 200)
Figure 3 Up-regulation of IL-6 mRNA in human oesophageal carcinoma cell
lines by n-BT. IL-6 mRNA was detected by RT-PCR. A 390-bp human
IL-6-specific sequence (upper panel) and a 900-bp b-actin sequence (lower
panel) were amplified from total RNA isolated from human ESCC cell lines,
analysed by agarose-ethidium bromide gel electrophoresis
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CHigh concentrations of IL-6 in the tumour homogenates further
suggest that tumour cells may produce IL-6. It should be clear that
the tumour cells produce IL-6 if they are seen by ISH. Not only
have we confirmed their finding by showing expression of IL-6
mRNA in the tumour cells by ISH, but also correlated the serum
IL-6 levels with disease progression and survival of patients with
ESCC. The serum levels of IL-6 were significantly higher in
patients with positive lymph node metastasis and the advanced
tumour stages. By demonstrating a similar IL-6 mRNA expression
in ESCC cell lines, our work suggests that this phenomenon could
be a general one. In the present study, the incidence of IL-6Ra in
pathological sections was 88.7%, and IL-6 mRNA was 37.5%.
Although the incidence of IL-6Ra is much higher than that of
IL-6 in pathological sections, expression of IL-6 may be induced
or enhanced by external stimulators, such as n-BT or other
carcinogens. Currently, we have shown that n-BT can induce or
enhance IL-6 mRNA expression in cancer cell lines as assayed by
ISH and semi-quantitative RT-PCR. Furthermore, the increase of
IL-6 mRNA expression is associated with a rise of IL-6 content in
the supernatant as assayed by ELISA. Though the clinical roles
of n-BT are evaluated in an ongoing study, as mentioned above,
our results indicate that IL-6 expression in cancer cells could be
potentially up-regulated by some external stimulators, such as
n-BT. Not only could IL-6 be a prognostic predictor for the aggres-
siveness of ESCC, but also could elevated serum IL-6 reflect the
pathogenic significance in progression of the malignancy.
Our previous experience in the management of patients with
advanced T4 ESCC has shown that removal of tumour-bearing
mass followed by an aggressive concurrent radiochemotherapy
could provide significant improvement to patients than surgery
alone (Wang et al, 1996). Most patients who have a decrease of
IL-6 level following successful oesophagectomy remained
disease-free for 12–23 months. In patients with persistent high
levels of serum IL-6 or a marked increase of serum IL-6 level
within a short interval following surgery, recurrence and distant
metastasis of cancer were frequently found. However, a mixed
population of IL-6 expression cells (macrophage, plasma cells,
lymphocytes and tumour cells) was only found in three cases
(3.8%) of pathological sections. These data considered together
with our ESCC cell line studies clearly demonstrate that ESCC
cells can produce IL-6, and IL-6 expression in ESCC cells can be
up-regulated by n-BT and, maybe, a yet to be determined physio-
logical function.
The increased gene expression of IL-6 has been shown in
different types of human cells (fibroblasts, monocytes, epithelial
cells and endothelial cells) as a result of a number of different
stimuli, including tumour necrosis factor (TNF), IL-1, epidermoid
growth factor (EGF) viruses, endotoxin, diacylglycerol and
phorbol ester (TPA) (Ray et al, 1988). An increased level of
intracellular cAMP was suggested responsible for the induced
synthesis of IL-6 in human fibroblasts and HeLa cells (Ray et al,
1988; Zhang et al, 1988). However, upon examination of TPA
effect on ESCC cell lines, no induction of IL-6 expression was
observed (data not shown). Instead, synthesis and release of IL-6
in ESCC cell lines can be stimulated by n-BT. This phenomenon
has not been demonstrated previously and is somewhat surprising.
In fact, effect of n-BT on signal transduction pathway of calmod-
ulin and calcineurin together with its relationship to the gene acti-
vation has been well documented (Chow et al, 1997). As noted
above, both elevated urinary butyrate concentration and IL-6 level
were shown in the AIDS patients with immune impairment and
significant weight loss (Stein et al, 1997). In a cancer patient who
developed cachexia, the immune compromised condition is similar
to that of AIDS patient at the terminal stage. Detection of the
increased expression of IL-6 could be therefore anticipated in
many cancer patients as their conditions deteriorated. There is a
good reason then to believe that IL-6–IL-6R loop may play an
important role in autocrine growth of tumour cells (Kawano et al,
1988; Miki et al, 1989; Blay et al, 1992; Ni and O’Neill, 1992;
Kabir and Daar, 1995; Oka et al, 1996; Wojciechowska-Lacka
et al, 1996; Seymour et al, 1997). Nonetheless, these have not been
consistently found for all the cancer cells in a given tumour type
(Baba et al, 1995; Yanagawa et al, 1995).
The impact of IL-6 on tumour cell proliferation remains to be
clarified if this is the basis of tumour growth. It should be noted,
however, that other explanations are possible. In fact, tumour
progression is a concerted process including evasion of host
immunosurveillance (Chow and Chen, 1995), tumour cell self-
proliferation (Kawano et al, 1988; Miki et al, 1989; VanMeir et al,
1990; Watson et al, 1990; Ni and O’Neill, 1992; Eustace et al,
1993; Oka et al, 1996; Takeuchi et al, 1996), killing of the immune
cells (Walker et al, 1997) and invasion of neighbouring tissues as
well as the distant organs. Association of IL-6 with cell attach-
ment, migration and invasion was recently demonstrated by Obata
et al (1997) on human ovarian carcinoma. At the present time, our
results showed that serum levels of IL-6 were frequently elevated
in patients with ESCC (> 90%), and the high serum IL-6 levels
(³ 9 pg ml–1) may indicate a poor prognosis. Expression of IL-6 in
cancer cells could be up-regulated by n-BT, a short-chain fatty acid
produced by intestinal bacteria, certainly could indicate more
implication on the host immunosurveillance in intestine during
disease progression. Although there is not yet a clear explanation
for the clinical correlation between increased IL-6 expression in
cancer cells and disease progression, the observation provides a
focus for future studies to elucidate the mechanism by which
expression of IL-6 was regulated pathologically.
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